Product revenue was $67.0 million in the first quarter of 2014, compared with $62.7 million for the first quarter of 2013, an increase of 7 percent. Total revenue for the first quarter of 2014 was $67.0 million, compared with $63.1 million in the first quarter of 2013.
International product revenue grew by 35 percent to $11.5 million compared to the same period last year and represented 17 percent of product revenue in the first quarter of 2014.
Net loss in the first quarter of 2014 was $7.4 million, compared with net loss of $0.9 million in the first quarter of 2013. Basic and diluted net loss per share applicable to common stockholders was $0.24 for the first quarter of 2014, compared with a basic and diluted net loss per share of $0.03 for the same period in 2013.
"In the first quarter, we again expanded our U.S. breast cancer penetration, achieved strong international growth and drove adoption of our prostate cancer test," said Kim Popovits, Chairman of the Board, Chief Executive Officer and President of Genomic Health. "We are executing on our planned investments to maximize significant international and prostate opportunities, and are on track to report topline results from additional pivotal studies in DCIS breast and prostate cancer mid-year."